XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

• ClinicalTrials.gov Identifier: NCT03511183
• Recruitment Status: Unknown
• First Posted: April 27, 2018
• Last Update Posted: May 1, 2018
• Sponsor: Harbin Medical University
• Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Fudan University; Sun Yat-sen University; First Affiliated Hospital of Harbin Medical University; The Second Affiliated Hospital of Harbin Medical University; Liaoning Tumor Hospital & Institute; Shengjing Hospital; The First Hospital of Jilin University; The First Affiliated Hospital of Dalian Medical University; Jilin Provincial Tumor Hospital; The First People's Hospital of Jingzhou
• Information provided by (Responsible Party): Yu Han, Harbin Medical University

Study Description

Brief Summary:

Colorectal cancer will be resistant to Chemotherapy drugs after treated for a period of time .In the past, the classical treatment regiment was to change other drug after tumor progressed. In theory, the continuous use of such a drug could shortening the patient's drug resistance time. It has been shown that the alternate use of the two drug combinations is reasonable in clinical. This application can not only further improve the curative effect but also significantly reduce the side effects. So the investigators are going to carry out a prospective phase II clinical study. The control group change to second-line treatment after progression of first-line drugs. The experimental group use the first line and the second line,alternately, for every two cycles. The combination of bevacizumab is a first line development, and the second line can still be used . Objective to compare the clinical value of XELOX + bevacizumab and XELIRI + bevacizumab alternation regimen in the first-line treatment of advanced colorectal cancer.

Condition or disease	Intervention/treatment	Phase
Colorectal Neoplasms; Chemotherapy	Drug: XELIRI + bevacizumab; Drug: XELOX + bevacizumab	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 66 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized, Open, Controlled, Multicenter,Phase II Clinical Trial of XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer
• Actual Study Start Date: March 1, 2018
• Estimated Primary Completion Date: December 1, 2019
• Estimated Study Completion Date: June 1, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: alternative regiment; The first stage:XELOX + bevacizumab chemotherapy and XELIRI + bevacizumab chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage. The second stage: continue to apply another plan until there is progress or intolerance.	Drug: XELIRI + bevacizumab; Irinotecan，200mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle; Drug: XELOX + bevacizumab; Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
Placebo Comparator: classical regiment; Use the XELOX + bevacizumab chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI + bevacizumab chemotherapy until there is progress or intolerance.	Drug: XELIRI + bevacizumab; Irinotecan，200mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle; Drug: XELOX + bevacizumab; Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle

Outcome Measures

Primary Outcome Measures :

1. Adverse Events [ Time Frame: 22 months ]
   Adverse events will be evaluated according to NCI CTCAE 4.0
2. Time to failure of strategy（TFS） [ Time Frame: 22 months ]
   Time from the beginning of the treatment until appear the following events, including death and implementation.the progress of disease,

Secondary Outcome Measures :

1. Objective response rate (ORR) [ Time Frame: 22 months ]
   The proportion of patients whose tumor is reduced to a certain amount and maintain a certain period of time.
2. Disease control rate(DCR) [ Time Frame: 22 months ]
   The rate of cases of remission and stable disease accounts for the total evaluable cases after treatment
3. Overall Survival (OS) [ Time Frame: 22 months ]
   Overall survival time after the beginning of the treatment
4. Time to failure of strategy（TFS） [ Time Frame: 22 months ]
   Time from the second beginning of the treatment until appear the following events, including death and implementation.the progress of disease,

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Diagnosed as colorectal adenocarcinoma by histopathology and/or cytology.
2. Patients could not receive surgical resection.
3. Never received chemotherapy or radiotherapy.
4. According to the RECIST v1.1 guide, at least 1 lesions (never received radiotherapy),accurately measured by computed tomography (CT) or magnetic resonance imaging (MRI) (intravenous contrast agent as the first choice),the longest diameter was more than 10mm (except for the lymph nodes, the short axis of the lymph nodes must be more than 15mm), repeated measurement.
5. Eastern Cooperative Oncology Group Performance Status(ECOG PS):0-1 score

6. The main organs function is normal, which meets the following requirements. (1) Blood routine examination,(no blood transfusion within 14 days).

   1. Hemoglobin(HB)≥90g/L;
   2. Absolute neutrophil count (ANC) ≥1.5×10^9/L;
   3. Blood platelet (PLT)≥80×10^9/L; (2) Biochemical examination should comply with the following criteria:
   1. Bilirubin(BIL) <1.5 times of the upper limit of normal value (ULN)
   2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)<2.5*ULN (liver metastasis ALT and AST<5*ULN).
   3. Serum Cr≤1*ULN, creatinine clearance rate≥50ml/min (Cockcroft-Gault formula)
7. The expected survival time more than 3 months;
8. The physicians plan to use XELOX + bevacizumab chemotherapy or XELIRI+bevacizumab chemotherapy.
9. Patients voluntarily joined the study and signed informed consent form (ICF).
10. Child bearing age women must undergo a negative pregnancy test (serum or urine) within 7 days ,and voluntarily adopt appropriate methods for contraception from the period of under observation and within 8 weeks of the last time they are given the drug; As for men, it is necessary to receive surgical sterilization, or agree to adopt appropriate methods for contraception from the period of under observation and within 8 weeks of the last time they are given the drug.

Exclusion Criteria:

1. There is a case of heart disease in any of the following situations. (1)Recent publications have the following heart disease (within 6 months)

   1. Acute coronary artery syndrome
   2. Acute heart failure (grade III or IV of NYHA classification)

   3. Significant ventricular arrhythmia(sustained ventricular tachycardia, ventricular fibrillation and sudden death after resuscitation).

      (2)The New York Heart Association(NYHA) grade of grade III or IV (3)The patients with severe conduction block, and permanent pacemaker is invalid (two degree and three degree atrioventricular block, sinus arrest) (4)Unexplained syncope occurred within 3 months. (5)The researchers identified as uncontrol of severe hypertension, or symptomatic hypertension.

2. There are many factors that affect the absorption of oral drugs (such as unable to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction).
3. ECOG score≥2
4. Abnormal coagulation function (INR>1.5*ULN, Activated partial thromboplastin time(APTT)>1.5*ULN), with bleeding tendency.
5. There is any history of allergy or hypersensitivity in this research's drug or adjuvant.
6. HIV infection and/or active hepatitis B virus infection.
7. Any condition that may damage the safety of patients or the integrity of research data, including serious medical risk factors, physical condition and laboratory abnormality.
8. The high risk population carrying UGT1A1*28 (7/7) *6 (A/A) genotype or simultaneous carrying of the UGT1A1*28 (6/7) *6 (A/G) genotype (the heterozygous genotype) suggests the exclusion of the Irinotecan
9. Pregnant or lactating women;
10. Other conditions which the doctor think not suitable for inclusion.

Contacts and Locations

Contacts

Contact: Yu Han, doctor; +86-451-86298303; hanyuemail@163.com

Locations

China, Heilongjiang

Harbin Medical University; Recruiting

Harbin, Heilongjiang, China

Contact: Yu Han, doctor

Sponsors and Collaborators

Harbin Medical University

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Fudan University

Sun Yat-sen University

First Affiliated Hospital of Harbin Medical University

The Second Affiliated Hospital of Harbin Medical University

Liaoning Tumor Hospital & Institute

Shengjing Hospital

The First Hospital of Jilin University

The First Affiliated Hospital of Dalian Medical University

Jilin Provincial Tumor Hospital

The First People's Hospital of Jingzhou

More Information

• Responsible Party: Yu Han, Chief physician, Harbin Medical University
• ClinicalTrials.gov Identifier: NCT03511183
• Other Study ID Numbers: 2018-51-IIT
• First Posted: April 27, 2018
• Last Update Posted: May 1, 2018
• Last Verified: April 2018

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Bevacizumab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Physiological Effects of Drugs; Growth Inhibitors